- Home
- EDN vs PHAT Comparison
EDN vs PHAT Comparison
Compare EDN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | PHAT |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 969.8M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDN | PHAT |
|---|---|---|
| Price | $22.98 | $9.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 87.7K | ★ 1.3M |
| Earning Date | 03-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $13.19 | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $14.38 | $8.21 |
| 52 Week High | $36.70 | $18.31 |
Technical Indicators
Market Signals| Indicator | EDN | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 42.85 |
| Support Level | $22.21 | $8.78 |
| Resistance Level | $29.64 | $9.75 |
| Average True Range (ATR) | 1.15 | 0.44 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 38.45 | 35.32 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires, mainly for residential, commercial, industrial, and public service.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.